| 货号 | MAB2131-500 |
| 别名 | ALRHMGC116789; BHR1interleukin-13; IL-13MGC116788; interleukin 13; MGC116786; NC30; P600 | 全称 | Interleukin 13 |
| 反应种属 | Human |
| 应用 | Western Blot(1 µg/mL) Flow Cytometry(2.5 µg/106cells) |
| 目标/特异性 | Detects human IL-13 in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross-reactivity with recombinant human IL‑4 or recombinant mouse IL-13 is observed. |
| 使用方法 | Western Blot: 1 µg/mL Flow Cytometry: 2.5 µg/106cells Neutralization: Measured by its ability to neutralize IL‑13-induced proliferation in the TF‑1 human erythroleukemic cell line. Kitamura, T. et al. (1989) J. Cell Physiol. 140:323. The Neutralization Dose (ND50) is typically 1-4 µg/mL in the presence of 10 ng/mL Recombinant Human IL‑13. |
| 来源 | Monoclonal Mouse IgG1 Clone # 31606 |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 3596 (Human); 16163 (Mouse); 116553 (Rat); 574325 (Primate) |
| 应用文献 | |
| R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions. Human CD8+ T-cells recognizing peptides from Mycobacterium tuberculosis (Mtb) presented by HLA-E have an unorthodox Th2-like, multifunctional, Mtb inhibitory phenotype and represent a novel human T-cell subset. | |
| 纯化方式 | Protein A or G purified from ascites |
| 免疫原 | E. coli-derived recombinant human IL-13 Gly35-Asn146 Accession # P35225 |
| 内毒素水平 | <0.10 EU per 1 μg of the antibody by the LAL method. |
| 生物活性 | Human |
| 标记 | Unconjugated |
| 溶解方法 | Reconstitute at 0.5 mg/mL in sterile PBS. |
| 背景 | IL-13 is a 17 kDa immunoregulatory cytokine that plays a key role in the pathogenesis of allergic asthma and atopy. It is secreted by Th1 and Th2 CD4+ T cells, NK cells, visceral smooth muscle cells, eosinophils, mast cells, and basophils (1-3). IL-13 circulates as a monomer with two internal disulfide bonds that contribute to a bundled four alpha -helix configuration (4, 5). Mature human IL-13 shares 57%, 59%, and 94% amino acid sequence identity with mouse, rat, and rhesus IL-13, respectively. Despite the low homology, it exhibits cross-species activity between human, mouse, and rat (6, 7). IL-13 has diverse activities on numerous cell types (8). On macrophages, IL-13 suppresses the production of proinflammatory cytokines and other cytotoxic substances. On B cells, IL-13 induces immunoglobulin class switching to IgE, upregulates the expression of MHC class II, CD71, CD72, and CD23, and costimulates proliferation. IL-13 upregulates IL-6 while downregulating IL-1 and TNF-alpha production by fibroblasts and endothelial cells. IL-13 binds with low affinity to IL-13 R alpha 1, triggering IL-13 R alpha 1 association with IL-4 R alpha. This high affinity receptor complex also functions as the type 2 IL-4 receptor complex (9, 10). Additionally, IL-13 binds with high affinity to IL-13 R alpha 2 which is expressed intracellularly, on the cell surface, and as a soluble molecule (11-14). IL-13 R alpha 2 regulates the bioavailability of both IL-13 and IL-4 and is over-expressed in glioma and several bronchial pathologies (10, 15, 16). Compared to wild type IL-13, the atopy-associated R110Q variant of IL-13 elicits increased responsiveness from eosinophils that express low levels of IL-13 R alpha 2 (17). |
| 运输条件 | Blue Ice |
| 存放说明 | -20℃ |
| 参考文献 |
|
Detection of IL‑13 in Human PBMCs by Flow Cytometry. Human peripheral blood mononuclear cells (PBMCs) treated with 5 ng/mL Recombinant Human IL‑4 (Catalog # 204-IL) and 10 µg/mL Goat Anti-Human IFN‑ gamma Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-285-NA) for 3 days were stained with Mouse Anti-Human IL‑13 Monoclonal Antibody (Catalog # MAB2131) followed by Allophycocyanin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B) and Mouse Anti-Human CD4 PE-conjugated Monoclonal Antibody (Catalog # FAB3791P). Quadrant markers were set based on control antibody staining (Catalog # MAB002). | |
Cell Proliferation Induced by IL‑13 and Neutralization by Human IL‑13 Antibody. Recombinant Human IL‑13 (Catalog # 213-ILB) stimulates proliferation in the TF‑1 human erythroleukemic cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human IL‑13 (10 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human IL‑13 Monoclonal Antibody (Catalog # MAB2131). The ND50 is typically 1-4 µg/mL. |
